Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБОУ ВО «Санкт-Петербургский государственный университет», Россия 2 ЗАО «Фармфирма Сотекс»
Список исп. литературыСкрыть список 1. Sher L. The impact of the COVID-19 pandemic on suicide rates [published online ahead of print, 2020 Jun 15]. QJM. 2020; hcaa202. doi: 10.1093/qjmed/hcaa202 2. Ko CH, Yen CF, Yen JY, Yang MJ. Psychosocial impact among the public of the severe acute respiratory syndrome epidemic in Taiwan. Psychiatry Clin. Neurosci. 2006; 60: 397–403. 3. Zhang, J. et al. The differential psychological distress of populations affected by the COVID-19 pandemic. Brain Behav. Immun. 2020. https://doi.org/10.1016/j.bbi.2020.04.031 4. Петрова Н.Н., Морозов П.В., Маркин А.В., Беккер Р.А., Быков Ю.В. Пандемия COVID-19: актуальные вызовы времени, а также новейшие данные к вопросу рационального выбора психофармакотерапии у пациентов с SARS-COV-2. Психиатрия и психофармакотерапия. 2020; 22 (6): 8–24. 5. Benedetti F, Poletti S, Hoogenboezem TA, Locatelli C, de Wit H, Wijkhuijs AJM, Colombo C, Drexhage HA. Higher Baseline Proinflammatory Cytokines Mark Poor Antidepressant Response in Bipolar Disorder. J Clin Psychiatry. 2017;78(8):986-993. doi: 10.4088/JCP.16m11310. Benedetti F, Aggio V, Pratesi ML, Greco G, Furlan R. Neuroinflammation in Bipolar Depression. Front Psychiatry. 2020; 11: 71. Published 2020 Feb 26. doi:10.3389/fpsyt.2020.00071 6. Mazza MG, De Lorenzo R, Conte C, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020; 89: 594–600. doi:10.1016/j.bbi.2020.07.037 7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5 8. Pierce M et al. Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. Lancet Psychiatry. 2020; 7: 883–92. 9. Panchal N. The Implications of COVID-19 for Mental Health and Substance Use, KFF, 2020. 10. Taquet M., Geddes J.R., Husain M., Luciano S., Harrison P.J. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet Psychiatry. 2021; 8 (5): 16–27. 11. Taquet M., Luciano S., Geddes J.R., Harrison P.J. Bi-directional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The lancet Psychiatry. 2020 Nov 9;S2215-0366;(20):30462–4. 12. Мосолов С. Н. Длительные психические нарушения после перенесенной острой коронавирусной инфекции SARS-CoV-2. Современная терапия психических расстройств. 2021; 3: 2–23. doi10.21265/ PSYPH.2021.31.25.001 13. Writing Committee for the COMEBAC Study Group, Morin L., Savale L., et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA 2021; 325: 1525. 14. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020; 7 (7): 611–27. doi:10.1016/S2215-0366(20)30203-0 15. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 2021; 372:n693 16. Chaolin Huang Lixue Huang Yeming Wan gXia LiLili Ren Xiaoying Guand others 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet Vol. 397No. 10270p220–232Published: January 8, 2021. doi:10.1016/S0140-6736(20)32656-8 17. Медведев ВЭ, Доготарь ОА. COVID-19 и психическое здоровье: вызовы и первые выводы. Неврология, нейропсихиатрия, психосоматика. 2020; 12(6): 4–10. DOI: 10.14412/2074-2711-2020-6-4-10 18. Мосолов С.Н., Малин Д.И., Цукарзи Э.Э., Костюкова Е.Г. Особенности психофармакотерапии пациентов с коронавирусной инфекцией (COVIDJ19). Современная терапия психических расстройств. 2020; 2. DOI: 10.21265/PSYPH.2020.18.69.001 19. Малин Д.И., Рывкин П.В. Безопасность применения психотропных средств при осложнениях COVID-19. Современная терапия психических расстройств. 2021; 1: 15–22. DOI: 10.21265/PSYPH.2021.63.59.003 20. Мосолов СН. Проблемы психического здоровья в условиях пандемии COVID-19. Журнал неврологии и психиатрии им. С. С. Корсакова. 2020; 120(5): 7–15. DOI: 10.17116/jnevro20201200517 21. Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, Borsini A, Casanova Dias M, Tamouza R, Leboyer M, Benros ME, Branchi I, Fusar-Poli P, De Picker LJ. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021 Sep;8(9):797-812. doi: 10.1016/S2215-0366(21)00232-7. Epub 2021 Jul 17. PMID: 34274033; PMCID: PMC8285121 22. Hoertel N, Sánchez-Rico M, Vernet R, , et al. AP-HP / Universities / INSERM COVID-19 Research Collaboration and AP-HP COVID CDR Initiative. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021 Feb 4. doi: 10.1038/s41380-021-01021-4. Epub ahead of print. PMID: 33536545. 23. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324 (22): 2292–300. 24. Seymour CW, Bauchner H, Golub RM. COVID-19 Infection–Preventing Clinical Deterioration. JAMA. 2020;324(22):2300 25. Seftel D, Boulware DR, Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19, Open Forum Infectious Diseases, Volume 8, Issue 2, February 2021. 26. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, de Souza Campos VH, Nogueira AMR, de Almeida APFG, Callegari ED, de Figueiredo Neto AD, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Glushchenko AV, Rayner CR, Lenze EJ, Reiersen AM, Guyatt GH, Mills EJ; TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2021 Oct 27:S2214-109X(21)00448-4. doi: 10.1016/S2214-109X(21)00448-4. Epub ahead of print. PMID: 34717820; PMCID: PMC8550952. 27. Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, Likic R. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol. 2021 Nov 1. doi: 10.1111/bcp.15126. Epub ahead of print. PMID: 34719789. Yesilkaya UH, Balcioglu YH, Sahin S. Reissuing the sigma receptors for SARS-CoV-2. J Clin Neurosci. 2020;80:72-73. DOI: 10.1016/j.jocn.2020.08.014 28. Albayrak Y, Hashimoto K. Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders. Adv Exp Med Biol. 2017;964:153-161. DOI: 10.1007/978-3-319-50174-1_11.; 29. Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19. Front Pharmacol. 2021 Apr 20;12:652688. doi: 10.3389/fphar.2021.652688. PMID: 33959018; PMCID: PMC8094534 30. Rosen DA, Seki SM, Fernández-Castañeda A et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11(478):eaau5266. DOI: 10.1126/scitranslmed.aau5266 31. https://www.covid19treatmentguidelines.nih.gov/immunomodulators/fluvoxamine 32. https://covid19criticalcare.com/covid-19-protocols/i-recover-protocol 33. Беккер РА, Быков ЮВ. Тревожные и диссомнические депрессии: клиника, диагностика, терапия и эффективность препарата Рокона® (флувоксамин). Психиатрия и психофармакотерапия им. П. Б. Ганнушкина.2019; 21(3): 17–23. 34. Беккер РА, Быков ЮВ. Флувоксамин: антидепрессант широкого спектра с рядом особенностей и преимуществ (обзор литературы). Психиатрия и психофармакотерапия им. П. Б. Ганнушкина. 2019; 21 (1): 11–26